USPTO allows patent covering levosimendan use in PH-HFpEF through 2040

TENAX THERAPEUTICS, INC.

USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.
Once granted, patent provides IP protection until Dec 2040, may qualify for patent term extension beyond 2040.
Third patent granted to Tenax since March 2023 protecting levosimendan for PH-HFpEF.
Phase 3 LEVEL study (NCT05983250) ongoing: 152 patients randomized, primary endpoint 6-minute walk distance at Week 12.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.